Dean B. Evans

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

Matthew J. Ellis, Andrew Coop, Baljit Singh et al. · Journal of Clinical Oncology · 2001 · 1.1K citations · Full text

Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Michael J. Ellis, Yu Tao, Jingqin Luo et al. · JNCI Journal of the National Cancer Institute · 2008 · 651 citations · Full text

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Carlos Garcı́a-Echeverrı́a, Mark Pearson, Andreas Marti et al. · Cancer Cell · 2004 · 535 citations · Full text

Cancer Research, Medicine, Receptor Tyrosine Kinase +9

Dual Inhibition of mTOR and Estrogen Receptor Signaling<i>In vitro</i>Induces Cell Death in Models of Breast Cancer

Anne Boulay, Joëlle Rudloff, Jingjing Ye et al. · Clinical Cancer Research · 2005 · 335 citations · Full text

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

Matthew J. Ellis, Andrew Coop, Baljit Singh et al. · PubMed · 2003 · 202 citations